Evidence map›Paper›PMID 34380535›Full record

ArticleMolecular neurodegeneration2021

Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures.

Melanie Barth, Mehtap Bacioglu, Niklas Schwarz, Renata Novotny, Janine Brandes, Marc Welzer, Sonia Mazzitelli, Lisa M Häsler, Manuel Schweighauser, Thomas V Wuttke and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Current preclinical models of brain metastasis.Clinical & experimental metastasis · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Modeling the Human Brain WithFrontiers in neuroscience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 4 countries.

Melanie BarthDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Mehtap BaciogluDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Niklas SchwarzDepartment of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72076, Tuebingen, Germany.
Renata NovotnyDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Janine BrandesDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72076, Tuebingen, Germany.
Marc WelzerDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Sonia MazzitelliDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Lisa M HäslerDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Manuel SchweighauserDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Thomas V WuttkeDepartment of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72076, Tuebingen, Germany.
Deborah Kronenberg-VersteegDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Karina FogDivision of Neuroscience, H. Lundbeck A/S, 2500, Valby, Denmark.
Malene AmbjørnDivision of Neuroscience, H. Lundbeck A/S, 2500, Valby, Denmark.
Ania AlikMIRCen, CEA and Laboratory of Neurodegenerative Diseases, CNRS, Institut François Jacob, 92265, Fontenay-aux-Roses, France.
Ronald MelkiMIRCen, CEA and Laboratory of Neurodegenerative Diseases, CNRS, Institut François Jacob, 92265, Fontenay-aux-Roses, France.
Philipp J KahleDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany.
Derya R ShimshekNeuroscience Research, Novartis Institutes for BioMedical Research, CH-4056, Basel, Switzerland.
Henner KochDepartment of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, 72076, Tuebingen, Germany.
Mathias JuckerDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany. mathias.jucker@uni-tuebingen.de.
Gaye TanriöverDZNE, German Center for Neurodegenerative Diseases, 72076, Tuebingen, Germany. gaye.tanrioever@uni-tuebingen.de.ORCID 0000-0002-5252-8443
German Center for Neurodegenerative Diseases · DEHertie Institute for Clinical Brain Research · DECentre National de la Recherche Scientifique · FRLundbeck (Denmark) · DKNovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProteopathic brain lesions are a hallmark of many age-related neurodegenerative diseases including synucleinopathies and develop at least a decade before the onset of clinical symptoms. Thus, understanding of the initiation and propagation of such lesions is key for developing therapeutics to delay or halt disease progression.

methodsAlpha-synuclein (αS) inclusions were induced in long-term murine and human slice cultures by seeded aggregation. An αS seed-recognizing human antibody was tested for blocking seeding and/or spreading of the αS lesions. Release of neurofilament light chain (NfL) into the culture medium was assessed.

resultsTo study initial stages of α-synucleinopathies, we induced αS inclusions in murine hippocampal slice cultures by seeded aggregation. Induction of αS inclusions in neurons was apparent as early as 1week post-seeding, followed by the occurrence of microglial inclusions in vicinity of the neuronal lesions at 2-3 weeks. The amount of αS inclusions was dependent on the type of αS seed and on the culture's genetic background (wildtype vs A53T-αS genotype). Formation of αS inclusions could be monitored by neurofilament light chain protein release into the culture medium, a fluid biomarker of neurodegeneration commonly used in clinical settings. Local microinjection of αS seeds resulted in spreading of αS inclusions to neuronally connected hippocampal subregions, and seeding and spreading could be inhibited by an αS seed-recognizing human antibody. We then applied parameters of the murine cultures to surgical resection-derived adult human long-term neocortical slice cultures from 22 to 61-year-old donors. Similarly, in these human slice cultures, proof-of-principle induction of αS lesions was achieved at 1week post-seeding in combination with viral A53T-αS expressions.

conclusionThe successful translation of these brain cultures from mouse to human with the first reported induction of human αS lesions in a true adult human brain environment underlines the potential of this model to study proteopathic lesions in intact mouse and now even aged human brain environments.

Indexed as

Synucleinopathiesalpha-SynucleinAnimalsHumansInclusion BodiesMiceMicrogliaNeurofilament ProteinsNeuronsOrgan Culture Techniquesalpha-Synucleinneurofilament protein LNeurofilament ProteinsAlpha-synucleinMicrogliaNeurofilament light chainSlice culture

Identifiers

PMID34380535
PMCPMC8356412
OpenAlexW3190395077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.